Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.
Covered in this story
What has happened since
- Biogen is up 4.2% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Biogen
- BMO Capital Markets: $229 → $220 by Oct 2027 · Market Perform via Investing.com
- Wolfe Research: $216 → $300 by Sep 2027 · Outperform via Yahoo Finance
- H.C. Wainwright: $203 → $251 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BIIB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Biogen →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.